Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NWL-NSCs is an autologous neural stem-like cell therapy developed by New World Laboratories for the treatment of central nervous system (CNS) disorders. The therapy utilizes a proprietary reprogramming process to convert a patient's own somatic cells, such as skin or blood cells, into neural stem-like cells without the use of genetic engineering. These personalized cells are designed for transplantation into the CNS to replace or repair damaged tissue, promoting regeneration while avoiding immunorejection. Preclinical studies have indicated superior regenerative potential compared to fetal neural stem cells, with no evidence of tumor or teratoma formation. The therapy is currently in the pre-IND stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NWL-NSCs.